secwatch / observer
8-K filed November 2, 2023, 7:59 PM ET ticker VRDN CIK 0001590750
leadership confidence high sentiment neutral materiality 0.30

Director Scott Myers resigns from Viridian board; company adopts amended bylaws effective Nov 1, 2023

Viridian Therapeutics, Inc.\DE

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Scott Myers

director
VRDN · Viridian Therapeutics, Inc.\DE
Effective
2023-10-29
Filed
November 2, 2023, 7:59 PM ET
On October 29, 2023, Scott Myers resigned as a member of the board of directors (the "Board") of Viridian Therapeutics, Inc. (the "Company"), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Myers resigned as director at Viridian Therapeutics, Inc.\DE.

Action
resigned
Role
director
Exact text from the filing
On October 29, 2023, Scott Myers resigned as a member of the board of directors (the "Board") of Viridian Therapeutics, Inc. (the "Company"), effective immediately.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Viridian Therapeutics, Inc.\DE: The Board adopted the Third Amended and Restated Bylaws, modifying the notice period required to call a special meeting of the Board (effective 2023-11-01).

Change
bylaw amendment
Effective
2023-11-01
Exact text from the filing
Effective November 1, 2023, the Board adopted the Third Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws, among other things, modify the notice period required to call a special meeting of the Board.
View on SEC.gov

71 governance changes filed in the last 30 days. Browse all governance changes →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR
accession 0001193125-23-269415
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.